US equities
|
NVDA
$162.85
▼-2.01%
AMD
$534.06
▼-8.75%
MU
$778.31
▼-2.52%
AAPL
$356.27
▲+0.39%
MSFT
$523.88
▲+0.17%
TSLA
$390.22
▼-1.82%
AVGO
$347.01
▼-4.76%
SNDK
$885.01
▼-5.59%
NVDA
$162.85
▼-2.01%
AMD
$534.06
▼-8.75%
MU
$778.31
▼-2.52%
AAPL
$356.27
▲+0.39%
MSFT
$523.88
▲+0.17%
TSLA
$390.22
▼-1.82%
AVGO
$347.01
▼-4.76%
SNDK
$885.01
▼-5.59%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
MiNK Therapeutics, Inc. - Common Stock
(NQ:
INKT
)
9.340
-0.190 (-1.99%)
Delayed Quote
Updated: 4:00 PM EST, Nov 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MiNK Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
MiNK Therapeutics (INKT) Q3 2026 Earnings Call Transcript
↗
November 11, 2026
First revenue lands as the ARDS trial enters randomized Phase II.
Via
The Motley Fool
Topics
Earnings
What MiNK Therapeutics (INKT) Said on Its Q3 Earnings Call
↗
November 11, 2026
MiNK Therapeutics (NASDAQ:INKT) has initiated a randomized Phase 2 trial of its investigational cell therapy agenT-797 in patients with severe acute lung injury and respiratory distress, with...
Via
MarketBeat
Topics
Earnings
MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
November 11, 2026
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics (NASDAQ:INKT) Posts Narrower-Than-Expected Q1 Loss, Advances iNKT Therapy Into Pivotal Testing
↗
May 15, 2026
Via
Chartmill
MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)
November 06, 2026
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
November 02, 2026
Webcast to highlight advancement of the randomized Phase 2 trial of agenT-797 in acute lung injury, the ARPA-H collaboration to advance deployable cell therapeutics, and new data released at the...
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
October 02, 2026
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
September 30, 2026
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
Net loss narrowed to $3.1 million as Phase 2 trial for agenT-797 advances in Ukraine.
Via
The Motley Fool
Topics
Earnings
MiNK Therapeutics Q2 Earnings Call Highlights
↗
August 13, 2026
MiNK Therapeutics (NASDAQ:INKT) said it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and...
Via
MarketBeat
Topics
Earnings
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
August 13, 2026
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium
August 06, 2026
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
August 06, 2026
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
June 03, 2026
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
May 28, 2026
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
May 20, 2026
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK (INKT) Q4 2025 Earnings Call Transcript
↗
May 15, 2026
MiNK (INKT) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
MiNK (INKT) Q1 2026 Earnings Call Transcript
↗
May 15, 2026
MiNK (INKT) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
MiNK Therapeutics Q1 Earnings Call Highlights
↗
May 15, 2026
MiNK Therapeutics (NASDAQ:INKT) said it is advancing its off-the-shelf invariant natural killer T cell therapy platform into a randomized clinical program for severe acute lung injury and acute...
Via
MarketBeat
Topics
Earnings
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
May 15, 2026
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
May 14, 2026
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
May 12, 2026
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
May 08, 2026
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
April 03, 2026
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
April 02, 2026
From
MiNK Therapeutics
Via
GlobeNewswire
These stocks are gapping in today's session
↗
April 01, 2026
Via
Chartmill
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
April 01, 2026
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
March 31, 2026
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs
March 17, 2026
Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potential
From
MiNK Therapeutics
Via
GlobeNewswire
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
March 11, 2026
Via
Chartmill
< Previous
1
2
3
4
5
6
7
Next >
